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The purpose of this study was to assess prescription rationality
and most common prescription errors at the primary care clinic
of a Mexican university.A retrospective drug utilization review of
indication-prescription type was carried out. A random sample of
370 medical records of patients assisted over a year period, were
reviewed. Prescription appropriateness was evaluated according
to the variables: indication, dosage regimen, administration route,
contraindications, interactions, medication duplicity, unnecessary
or missing medications. Prescriptions were rated as appropriate
(no prescription errors found) or inappropriate (at least one
prescription error found). The benefit-risk ratio was calculated
for each prescription. This study revealed a 58% of inappropriate
prescriptions in the Mexican primary care university clinic, mostly
due to errors on dosage regimen and innapropiate drug selection.
As a result of χ2 analysis, it was found that the pharmacotherapeutic
variables chosen for the prescription assessment in this study, were
determinant in prescription appropriateness rating. Nimesulide,
ciprofloxacin, ranitidine, ketorolac and paracetamol were the most
prescribed drugs as well as the most common cause of errors found.
The prescription error rate revealed by this study addresses the need
for strategies to improve prescription’s quality. Introducing
pharmacists as a key part of health care team is a mean proposed to
prevent medication errors and to solve the urgency of pharmaceutical
care implementation in all primary care facilities in Mexico.
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Nowadays, more than seven thousand registered
pharmaceutical products are commercialized in Mexico
and each year around 600 new products are introduced to
the Mexican market (Secretaría de Salud de México,
2005). This situation confronts Mexican general
practitioners at the primary care level, to a wide range of
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available medicines, conducting to a complex decision
making process in therapeutics.
Moreover, although the World Health Organization
(WHO) recommended since 1988 the inclusion of
pharmacists on the health care teams (Organización
Panamericana de la Salud, 1993), pharmacists have not yet
been completely recognized and accepted by the Mexican
health system as the health care professionals responsible
for promoting the correct use of medicines. There is still no
drug use monitoring in all Mexican health institutions, not
enough drug information centers (only six distributed in all
the country) and there are very few pharmacists
collaborating with other health care professionals in
hospitals and in Drug and Therapeutics Committees. Thus,
research on rational-drug-use in Mexico, identification of
the most frequent medication errors in public and private
health care facilities and implementation of strategies for
solving and preventing drug misadventures with full
participation of pharmacists, are actions still far away to be
routinely carried out.
WHO recently stated, that the irrational use of drugs
is increasing; one of the reasons is that medication use is
worse in the private health sector of underdeveloped
countries than in the public sector; in fact, the private sector
has become more active than the public sector increasing its
participation in health assistance around the world (World
Health Organization, 2006). The present study is the first
pharmacoepidemiological study published where drug
utilization is assessed in a private Mexican primary care
facility.
The National Coordinating Council for Medication
Error Reporting and Prevention (NCCMERP) defined a
medication error as “any preventable event that may cau-
se or lead to inappropriate medication use or patient harm
while the medication is in the control of the health care
professional, patient, or consumer. Such events may be
related to professional practice, health care products,
procedures, and systems, including prescribing; order
communication; product labeling, packaging, and
nomenclature; compounding; dispensing; distribution;
administration; education; monitoring; and use”
(NCCMERP, 2007).
The rational use of drugs begins with a correct
prescription; nevertheless, according to the consulted
literature, this stage is where more than 50% of all
treatments present errors (Otero et al., 1992; Tamblyn et
al., 2003; González et al., 2005). Some of the most
important situations that should be considered as
prescription errors are: a) errors during the decision making
process (drug not indicated, contraindicated drug, drug to
which the patient has a documented allergy or a significant
risk of presenting adverse reactions, drug-disease
interactions, drug-drug interactions, inappropriate drug for
age or clinical condition, medication duplicity, unnecessary
drugs, inappropriate dosage, dosage form, administration
route, concentration or frequency of administration); and b)
errors in prescription writing that may or may not affect the
patient (illegible, unclear or potentially error causing
written prescriptions, omissions, transcription errors)
(Otero et al., 1992; Tamblyn et al., 2003; ASHP, 1993;
Dean et al., 2000). In primary health care facilities, most
of these medication misadventures can only be classified as
potential errors, because there is little information whether
they actually reach the patient or not.
There is a lack of publications about the type and
frequency of occurrence of medication errors in primary
care. Medication error research at this level is limited
mostly because users of such services are not inpatients as
occurs in hospitals, also due to the elevated assistential
pressure (time, patient/physician, and consultation-time/
patient rates, among other reasons) and to the primary care
practitioners who are misinformed on events considered as
prescription errors (Generalitat de Catalunya, 2004).
Pharmacoepidemiologic studies are useful diagnostic
tools for identifying needs in quality improvement for
health services and in drug prescription. They are intended
to justify development of strategies and implementation of
health programs that may help correct deficient aspects
found throughout those studies (Hernández et al., 2000). In
1988, WHO found a low distribution of pharmacists in
underdeveloped countries and recommended those
countries to start research protocols at hospital and
community pharmacies in order to promote rational drug
use (Organización Panamericana de la Salud, 1993;
Bakker, 1996). Although some efforts have been already
done in Mexico and pharmacoepidemiologic studies have
been conducted in hospitals of some federal states like
Hidalgo (González, Viso, 2001; Viso et al., 2003; López-
Sánchez et al., 2001; Montaño, Viso, 2000), there is still a
low probability of finding a pharmacist at any hospital,
health care facility or community pharmacy.
The present study has been conducted at the primary
care facility of UDLA university campus, in the state of
Puebla, Mexico. At this health care unit, approximately
10.000 medical consultations are given each year, free of
charge to students, academic and administrative staff as
well as direct relatives of them.
Although since year 2000 there is pharmacy
undergraduate program at this university, no prior
initiatives have been made to introduce UDLA pharmacy
students to professional practices before; by detecting,
solving, monitoring and preventing medication errors at the
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university primary care unit, and actively promoting at the
same time in Mexico, the role of pharmacists as health care
providers.
The aim of this study was to detect the most frequent
prescription errors in this facility, through an indication-
prescription pharmacoepidemiologic methodology, in order
to justify the implementation of pharmaceutical care
services at the institution as well as the inclusion of
pharmacists as part of the health care team.
METHODS
A retrospective drug use review of indication-
prescription type (Figueiras et al., 2000) was carried out at
a primary care university unit. 370 medical records were
randomly chosen (“RANDOM”) function, Microsoft
Office Excel 2003) and reviewed as a sample (95%
confidence level) of the total of medical consultations (n=
9.874 prescriptions) attended from January to December
2004. Only complete records of adult male and female
patients (>17 years-old) were included in this study.
Confidentiality of patients´ identities were kept by
assigning an identification code to each medical record.
Data on patient demographics, indication for each
medication, dosage, dosage form, regimen and concurrent
medications were collected. Data on duration of medication
was not reported in the prescriptions and could not be
evaluated.
Appropriateness of prescription was evaluated
according to the following pharmacotherapeutic variables:
indication, dosage regimen (dose and frequency),
administration route, contraindications, potential
interactions, medication duplicity, unnecessary or missing
medications. These variables were chosen after consensing
several rational drug use and medication error definitions
(WHO, 2006; Dean et al., 2000; Cobaugh, Krenzelok,
2006). Judgements of appropriateness were established by
comparing the therapy given with primary, secondary and
tertiary bibliographic sources containing objective,
accurate, reliable and unbiased drug information and
pharmacotherapeutic guidelines (Dipiro et al., 2005;
McEvoy, 2006a; Randall, Neil, 2004; McEvoy, 2006b).
Prescriptions were rated as “appropriate” when no
errors were found according to pharmacotherapeutic
variables. “Inappropriate” prescriptions contained at least
one error for any of the variables assessed.
Non-parametric chi square tests of independence
were used to analyze the evaluated variables and the
appropriateness of prescriptions with a confidence level of
95% and a significance level of p<0.05 (Statgraphic 5.1 for
Windows 2001).
Since our study was retrospective, we were not able
to do interventions to correct prescription errors found and
it was impossible to know if “inappropriated” prescriptions
caused harm to the patient because medical records did not
contain information about it.
The benefit-risk ratio was calculated for each
prescription according to equation 1.1, adapted from
criteria used by Lyle et al. and Ramos et al. (Lyle et al.,
1979; Ramos et al., 2003).
equation 1.1:
benefit-risk ratio = (B1+B2+B3)/(R1+R2+R3)
To quantify this ratio, a score for each indicator
(benefit and risk) was established (s. Table I).
A benefit-risk ratio < 1 pointed out prescriptions
where pharmacotherapy decisions were more risky than
beneficial for the patients´ clinical condition. A benefit-risk
ratio > 1 was obtained for prescriptions where pharmaco-
therapy choices were more beneficial than risky.
Prescriptions with a benefit-risk ratio equal to 1 had the
same probability to benefit than to harm the patient.
The benefit-risk ratio was obtained for each
medication and an average of all ratios was calculated. The
total of prescriptions with a ratio > 1 and < 1 were
calculated.
RESULTS
A sample of 370 prescriptions was evaluated; 60% of
the patients of the sample were female and 40% were male.
Mean ±SD age was 26±11 years old and 73% of the
patients were between 17-26 years old. The most frequent
diagnoses were: diseases of respiratory system (30.5%);
injury, poisoning and certain other consequences of
external causes (11.7%); and diseases of the digestive
system (11.4%) (s. Table II).
At least 2 drugs were prescribed to 64% of the
patients, with a mean ± SD of 1.9 ± 0.9 drugs per patient.
For the 394 different health problems diagnosed to the
patients of the sample, a total of 722 medications (280
different drugs) were prescribed, and only 20 of them
(7.1%) were prescribed by its generic name.
75% of the drugs prescribed belong to M, J, R and A
groups of the Anatomical-Therapeutic-Chemical
Classification (ATC) (s. Table III). Most prescribed drug
were: nimesulide (25% of total prescriptions), followed by
ciprofloxacin (9.5%) and ranitidine (9.5%) (s. Table IV).
Due to the retrospective nature of this study, all
identified medication errors belonged to the category of
prescription errors. 214 (58%) of the sample of 370
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TABLE I - Benefit/Risk ratio assessment of the prescriptions
Indicators related to pharmacotherapeutic benefit of the prescription
Benefit 1 (B1) Benefit 2 (B2) Benefit 3 (B3)
Appropriateness of the prescription Dosage regimen Presence of beneficial drug interactions
according to the indication in the prescription
20 points: If drug was of first 25 points: Dose and frequency 20 points: More than two beneficial
choice for the indication were appropriate (individualized) drug interactions
10 points: If drug was not of first for the patient´s indication 10 points: One to two beneficial drug
choice for the indication 10 points: Dose and frequency interactions
5 points: If drug is not indicated were inappropriate for the 5 points: No beneficial drug
patient´s indication interactions
Indicators related to pharmacotherapeutic risk in the prescription
Risk 1 (R1) Risk 2 (R2) Risk (R3)
Drug interaction risk in the Medication duplicity Unnecessary medications
prescriptions
20 points: More than 2 risky 20 points: More than two drugs 20 points: More than one medication
drug interactions were prescribed for the same was unnecessary
10 points: One to two risky indication and only one of 10 points: One medication was
drug interactions them was necessary unnecessary
5 points: No risky drug interactions 10 points: Two drugs were 5 points: No unnecessary medications
prescribed for the same indication found
and only one of them was necessary
5 points: No medication duplicity
TABLE II - Most frequent diagnoses for the patients of the sample (n=370). *ICD = International Classification of Diseases
by World Health Organization
ICD code Chapter Number of patients
n (%)
J00 – J99 Diseases of the respiratory system 120 (30.5)
S00-T99 Injury, poisoning and certain other consequences of external causes 46 (11.7)
K00-K93 Diseases of the digestive system 45 (11.4)
A00-A09 Intestinal infectious diseases 35 (8.9)
M00-M99 Diseases of the musculoskeletal system and connective tissue 32 (8.1)
N00-N99 Diseases of the genitourinary system 24 (6.1)
H00-H59 Diseases of the eye and adnexa 15 (3.8)
L00-L99 Diseases of the skin and subcutaneous tissue 13 (3.3)
R00-R99 Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified 13 (3.3)
G00-G99 Diseases of the nervous system 10 (2.5)
prescriptions were rated as “inappropriate” with a mean ±
SD of 1.3 ± 0.6 errors per each inappropriate prescription.
In total, 268 prescription errors were found. As a result of
χ2 analysis, it was found that the pharmacotherapeutic
variables chosen for the prescription assessment in this
study were determinant in prescription appropriateness
rating, demonstrating also that the assessed variables were
correctly selected (s. Table V).
92 prescriptions were rated as “inappropriate”
because of discrepancies in indication and 78% of them
were rated so because of use of second-line drugs or drugs
not indicated for the patient’s clinical condition.
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TABLE III - Most frequently prescribed therapeutic groups according to first level of ATC Classification by WHO
Collaborating Centre for Drug Statistics Methodology
                  First level of ATC Classification Number of patients
n (%)
M Muscle-Skeletal System 203 (28.1)
J Antiinfectives for Systemic Use 116 (16.0)
R Respiratory System 114 (15.8)
A Alimentary Tract and Metabolism 110 (15.2)
N Nervous System 50 (6.9)
D Dermatologicals 31 (4.3)
G Genito-Urinary System and Sex Hormones 21 (2.9)
H Systemic Hormonal Preparations, excl. Sex Hormones and Insulins 10 (1.4)
S Sensory Organs 9 (1.2)
C Cardiovascular System 6 (0.8)
B Blood and Blood Forming Organs 5 (0.7)
P Antiparasitic Products, Insecticides and Repellents 4 (0.6)
Not classified 43 (6.0)
Total 722
TABLE IV - Most prescribed drugs according to fourth level of ATC classification by WHO Collaborating Centre for Drug
Statistics Methodology
ATC code Drug Administration Route Number of Patients
n (%)
M01AX17 Nimesulide Oral 47 (24.9)
J01MA02 Ciprofloxacin Oral 18 (9.5)
A02BA02 Ranitidine Oral 18 (9.5)
M01AB15 Ketorolac Oral 16 (8.5)
M01AE53 Paracetamol / Ketoprofen Oral 14 (7.4)
J01CA04 Amoxicillin Oral 12 (6.3)
M01AB15 Ketorolac Parenteral 12 (6.3)
Lactobacillus Boucardii strain Oral 12 (6.3)
N02BE01 Paracetamol Oral 12 (6.3)
A03AA05 Trimebutine Oral 12 (6.3)
One example, was the prescription of telithromycin
(J01FA15) for the empirical treatment of pharyngitis (J00
y J02.9) without justification, because there were no
microbiologic studies showing that the infection was
caused by macrolid resistant bacteria and there was no
information on the patient’s medical record of being allergic
to betalactamic antibiotics. For other inappropriate
prescriptions because of incorrect indication, antibiotics
(trimethoprim/sulfamethoxazole J01EE01), proton-pump
inhibitors (lansoprazole A02BC03 and pantoprazole
A02BC02) and H2 antagonists (ranitidine A02BA02) were
incorrectly prescribed to patients with a diagnosis of colitis
(K52.9). Another example was the prescription of
cefalexine (J01DB01) to a patient whose medical record
mentioned being allergic to penicillin (J01CE01), and in
fact, the patient presented an allergic reaction reported a
few days later on the next visit’s record.
Of the 102 prescriptions rated as inappropriate
because of the variable dosage regimen, 66% had longer
dosage interval and 29% shorter dosage interval than
recommended, 6% had a supratherapeutic dose and 13% a
subtherapeutic dose. For example, nimesulide (M01AX17)
was incorrectly prescribed 15 times, because tablets of 100
mg were ordered in 8-hour or 24-hour dosing intervals
instead of in 12-hour dosing intervals as recommended.
6.5% of assessed prescriptions were rated as
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inappropriate for unnecessary medications and 2.2% for
missing medications, according to the patient‘s diagnosis.
One example of this, was the concomitant prescription of
valdecoxib (M01AH03), parecoxib (M01AH04) and the
diclofenac/misoprostol combination (M01AB55) for
lumbalgia (M54.9). In other cases, analgesics and
antipiretic drugs were missing when considered necessary.
In 3.8% of the prescriptions, the medication
discrepancies were categorized as medication duplicities,
where at least one of the drugs was repeated in the same
prescription. Paracetamol (N02BE01) was the most
duplicated drug, mainly in prescriptions for patients with
respiratory diseases, because it is one of the most common
active ingredients of several fever and cold and cough
medicines.
Potential drug-drug interactions were detected in
6.2% of all prescriptions. The most frequent interaction (14
prescriptions) was the concurrent prescription of
ketoprofen (M01AE03) with paracetamol (N02BE01),
followed by the concomitant prescription (in 3 cases) of
antacids (A02A) with ranitidine (A02BA02).
The pharmacotherapeutic variable with the lowest
frequency of error was administration route, with only 5
prescriptions categorized as inappropriate.
93.5% of the prescriptions showed a calculated
benefit/risk ratio greater than 1. The mean value of the
benefit/risk ratios of all assessed prescriptions was 2.5.
Non-steroidal anti-inflammatory drugs (NSAIDs)
and ranitidine were the drugs most frequently involved in
the prescriptions with a benefit/risk ratio smaller than 1,
mainly because of duplicity and unnecessary prescription.
All prescribing errors found were category B errors
according to the NCCMERP Index for Categorizing
Medication Errors Algorithm (NCCMERP, 2007), because
the retrospective character of this study prevented the
possibility of knowing if the errors reached the patient or
not, whether we did not know if the patient took the
medication exactly as it was ordered.
DISCUSSION
Our study reports that 58% of the analyzed primary
care medical records had at least one prescription error,
supporting previous findings of other authors (Marcellino,
Kelly, 2001). Our results are also similar to Kelly´s review
at drug-adverse-reaction reports published by Clin-Alert
from 1976 to 1995, where he found that a significant
number of medication errors were produced during the
prescription writing process, and the prescription of a
second-line drug for the patient´s indication as well as
prescribing an incorrect dosage, were the most observed
errors (Kelly, 2001). Kelly concluded that most fatal
adverse events could be preventable by physicians, nurses
or pharmacists in hospitals or primary care units by having
computational systems which could track potential and
actual medication errors to prevent or solve them, and by
having more pharmacists monitoring prescriptions and
taking care of patients (Kelly, 2001). Moreover, we
conclude that besides electronic prescribing systems and
the development of national policies to include pharmacists
in the health care team, Mexico needs also urgently drug
information and toxicological information centers, at least
one in each federal state, for improving rational drug use
and for doing surveillance of drug adverse reactions and
medication misadventures.
Dean et al. (2000) pointed out that a major problem
with interpreting quantitative prescribing error studies is
that the definition of an error used by the researchers is
TABLE V - Prescription appropriateness according to the pharmacotherapeutic variables assessed. χ2= 1144.38; freedom
degrees = 6; p<0.05; n= 370
Prescriptions
Pharmacotherapeutic Appropriate Inappropriate
Variables No. % No. %
Indication 278 75.1 92 24.9
Dosage regimen (dose and frequency) 268 72.4 102 27.6
Unnecesary medications 346 93.5 24 6.5
Medication Duplicity 356 96.2 14 3.8
Potential drug-drug interactions 347 95.9 23 6.2
Missing medications 362 97.8 8 2.2
Administration route 365 98.6 5 1.3
Total 156 42.2 214 57.8
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often ambiguous or not given at all, making comparisons of
error rates across the literature, hard to do. Taking their
research results into consideration, we defined explicitly in
our study, the pharmacotherapeutic variables assessed for
the identification and quantification of prescribing errors in
the study sample. We consensed several definitions at the
moment of choosing variables in order to categorize
prescriptions as appropriate or inappropriate (WHO, 2006;
Dean et al., 2000; Cobaugh, Krenzelok, 2006). Dean et al.
(2000) developed the following practitioner led consensus
definition of a prescribing error for use in quantitative
studies of their incidence: “a clinically meaningful
prescribing error occurs when, as a result of a prescribing
decision or prescription writing process, there is an
unintentional significant reduction in the probability of
treatment being timely and effective or increase in the risk
of harm when compared with generally accepted practice”.
According to Dean et al. (2000), some of the
situations that should be included as prescribing errors are:
prescription of a contraindicated drug, prescription of a
drug to which the patient has a documented clinically
significant allergy, potentially significant drug interaction,
prescribing a drug in a dose that is inappropriate for the
patient’s condition, prescribing a drug for which there is no
indication for that patient, prescribing two drugs for the
same indication when only one of the drugs is necessary,
continuing a prescription for a longer duration than
necessary (depending on the individual clinical situation)
and unintentionally not prescribing a drug for a clinical
condition for which medication is indicated (depending on
the individual clinical situation). On the other hand,
situations like prescribing by brand name should be
excluded as prescribing errors.
Other definition we took into consideration was that
of the Toxic Exposure Surveillance System (TESS) of the
American Association of Poison Control Centers, where a
“therapeutic error” is defined as “an unintentional deviation
from a proper therapeutic regimen that results in the wrong
dose, incorrect route of administration, administration to
the wrong person, or administration of the wrong
medication or product used as medication”. Also
considered as therapeutic errors in the TESS definition, are
the drug-drug and drug-food interactions resulting from
unintentional administration either drugs or foods
(Cobaugh, Krenzelok, 2006).
WHO established that “the rational use of drugs
involves medications available at the lowest possible cost,
prescribed to meet patients’ individual clinical needs, given
in appropriate doses and for adequate period of time”
(WHO, 2006). In this way, according to WHO terminology,
prescriptions could be classified as “rational” or
“irrational”, but in order to smooth those terms we used the
words “appropriate” or “inappropriate” to categorize
prescriptions.
We also explicitly defined the pharmacotherapeutic
indicators and their scores used for calculating the benefit-
risk ratio for each prescription, since publications where
detailed quantitative determination of this ratio and the
indicators to calculate it, are hard to find. The 214
prescriptions rated as “inappropriate” had mostly errors on
indication and dosage regimen of the prescribed
medications, thus being these pharmacotherapeutic
variables the determinant indicators chosen for the benefit-
risk ratio calculation.
Our study found that NSAIDs and antibiotics were
the most-prescribed drugs. This is in accordance with the
fact that the respiratory system diseases (ICD: J00-J99),
particularly the acute upper and lower respiratory
infections, and the injury, poisoning and certain other
consequences of external causes (ICD: S00-T99) had the
highest reported morbidity rates among our patients. The
diseases of the digestive system and the intestinal infections
diseases were other frequently found diagnoses. Though,
we found a high frequency of inappropriate empirical
selection and prescription of antibiotics, demonstrating the
need to standardize the drug selection process. For the same
diagnosis, several different antibiotics were empirically
ordered (and no information about microbiological studies
was found in the medical records), also second-line
antibiotics or contraindicated antibiotics for the type of
presumed infection were prescribed. Many examples were
prescriptions for rhinopharyngitis and acute pharyngitis
diagnoses, for which 6 and 11 different antibiotics were
empirically prescribed, respectively. We think that the
reason why general practitioners prescribed many different
medications for a single diagnosis at the primary care unit
where we did the present study, is because this clinic
belongs to the private health sector, and there is no essential
medicines list, nor institutional pharmacotherapeutic
guidelines limiting or regulating drug selection.
High frequency of nimesulide prescriptions showed
us that its use and its adverse reactions in Mexican
population need further investigation, since nimesulide has
been prohibited or limited in its utilization in several
countries, due to the increasing incidence of adverse
reactions, particularly hepatotoxicity (Francis, 2002;
Mahajan, Sharma, 2005; Paz, 2006).
Only 20 of the 280 different active substances
prescribed, were ordered by generic name. We think that
this fact may caused prescription errors due to medication
duplicity (3.8%), since prescribing using trade names
implicate the risk of duplicate when the physician does not
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exactly know which drug or drug combinations are
contained in the medication. Moreover, prescribing trade-
name drugs implicates a higher probability of confusing
Look Alike/Sound Alike drug names, thus prescribing a not
indicated medication that could harm the patient.
Five of the ten most prescribed drugs of this study
have generic versions available on the Mexican market
(“genéricos intercambiables” or bioequivalent drugs) and
approved by the Mexican health authorities (ciprofloxacin,
ranitidine, oral ketorolac, parenteral ketorolac, amoxicillin
and paracetamol). However, Mexican health professionals
and patients do not trust enough non-brand name
substitutes because of the existence on the market of several
pharmaceutical products (“innovators”, “bioequivalent
drugs”, “generics” and “similars”) that lead to
misunderstanding and confusion. We suppose that for this
reason, general practitioners in our study did not use
generic names for prescribing and did not even prescribe
bioequivalent drugs. We also think that a consequence of
this, was the medication duplicity errors found for
paracetamol, the seventh most prescribed drug in our study.
If physicians did not have enough information about drugs
contained in medications and they used to prescribe by
brand name, duplicities could appear and patient could be
exposed to supratherapeutic doses of certain drugs, as
observed in this study for paracetamol.
The duplicity errors that we found in this study,
happened mostly with NSAIDs, which is comparable to
other findings (Borrás et al., 2005).
Prescriptions with errors on the indication of the drug
were frequent (25%), justifying the inclusion of
pharmacists in patient care for advising physicians,
validating prescriptions and developing a pharmaco-
therapeutic guide along with the rest of the health care team.
A mean of 1.9 drugs was prescribed per patient per
visit. This was consistent with the low incidence of chronic
diseases treated at the studied clinic and most probably due
to the predominance of young patients seen at this unit.
Nimesulide, paracetamol, ketorolac and ketoprofen
were the drugs most frequently prescribed in combinations
of drugs that could lead to drug-drug interactions. The
potential risk to the patient could not be assessed and no
appropriate action could be taken because of the
retrospective nature of this study. One combination of
moderate clinical significance was paracetamol and
ketoprofen. It has been reported that this combination may
increase the nephrotoxic and gastrointestinal adverse
effects of both drugs administered alone (Stockley, 2007).
This drug-drug interaction was the most frequently
observed because of the existence of medications
containing both drugs on the Mexican market. These
medications are sold in Mexico as OTC-products and they
are prescribed and dispensed to patients of all ages.
Paracetamol/ketoprofen containing combination products
are licensed in Mexico, Uruguay and Paraguay, but not in
USA, Spain, United Kingdom, Argentina or Brazil
(Vademecum México, 2006).
Combined prescription of drugs with potential
hazardous drug-drug interactions reported in literature,
should be taken with caution and appropriate monitoring,
as well as with enough information for the patient. The
latter is particularly important in Mexico, because there are
no pharmacists advising patients at community
pharmacies, making self-medication an increasing public
health problem. Patients could then “copy” the prescription
habits of their physicians in their self-medication practices,
expanding irrational use of drugs.
Many studies suggest that lack of information about
the patient, such as diagnosis, race/ethnicity, age, weight,
history of allergies, nicotine and alcohol dependence, drug
abuse, renal/hepatic function, previous or concurrent
medications and laboratory data, could lead to majority of
the reported drug adverse reactions (Otero et al., 1992;
Kelly, 2001; Leape et al., 1995). We detected in our study,
that important data about the patient´s clinical history and
actual health condition, like the concomitant drug use and
toxic habits of the patients, was missing in the analyzed
medical records. This was a limitation for assessing
prescriptions but also for detecting unexpected risks of the
prescribed pharmacotherapy, since we could not monitor
patients neither know if errors on indication or potential
interactions reached them. We thus recommended to the
primary care clinic the optimization of the medical records.
The prescription errors detected in this study lead us
once again to determine the critical role of pharmacists
monitoring medication orders and documenting their
interventions toward reducing medication errors.
Drug utilization studies are the first efforts in Mexico
to identify prescription patterns and medication errors at
various levels of health care facilities, in order to position
Mexican pharmacists among primary health care
providers, to develop best practices in medication safety
and increase physicians´ awareness about medication
errors and how to prevent them.
CONCLUSIONS
This study revealed a relative high incidence of
inappropriate prescriptions in a Mexican primary care
university clinic comparable to reported in literature, due
to inappropriate dosage regimen and drug selection
according to patient´s indication. Nimesulide, cipro-
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floxacin, ranitidine, ketorolac and paracetamol were the
most prescribed drugs as well as the cause of the majority
of prescription errors, according to the pharmacothera-
peutic variables assessed. We demonstrated the need of
drug prescription validation done by pharmacists and of
pharmacotherapeutic guidelines supporting the selection of
drugs in primary care. Our study justified the role that
Mexican pharmacists should be playing for preventing
medication errors as a key part of the health care team, as
well as the urgency of pharmaceutical care implementation
in all Mexican healthcare levels for ensuring that
therapeutic outcomes are achieved.
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RESUMO
Erros de prescrição no Centro de Saúde de uma
Universidade: urgência de implementar Atenção
Farmacêutica no México
O objetivo deste trabalho foi avaliar a racionalidade das
prescrições como também os erros mais comuns nas pres-
crições emitidas pelo Centro de Saúde de uma Universi-
dade no México. Foi realizado um estudo retrospectivo de
utilização de medicamentos que requeria prescrição médi-
ca. 370 expedientes médicos foram aleatoriamente seleci-
onados e revisados, obtendo uma mostra estatísticamente
representativa do total de consultas médicas realizadas no
período de um ano. A validade da prescrição médica foi
feita utilizando as seguintes variáveis: indicação, doses re-
comendada, via de administração, contra-indicações,
interações, duplicação de medicamentos, medicamentos
desnecessários ou faltantes. As prescrições médicas foram
classificadas como: apropriada (se não foram encontrados
erros nas prescrições) ou inapropriada (se foram encontra-
das ao menos um erro na prescrição). A razão risco-bene-
ficio foi calculada para cada prescrição médica. O estudo
revelou alta incidência de prescrições inapropriadas no
Centro de Saúde da Universidade do México (58%), cau-
sada pelos erros nas doses recomendadas e na seleção do
medicamento relacionado com a necessidade do pacien-
te. Como resultado da análise χ2 , foi encontrado que as
variáveis fármaco-terapêuticas escolhidas neste estudo
para avaliar a prescrição médica, foram determinantes
para classificar as prescrições como apropriadas.
Nimesulide, ciprofloxacin, ranitidine, ketorolac e
paracetamol representaram o maior número de medica-
mentos prescritos assim como a maior causa de erros en-
contradas nas prescrições. É importante que um farma-
cêutico valide os medicamentos prescritos no Centro de
Saúde. Este estudo justifica o papel que os farmacêuticos
mexicanos deveriam desempenhar para evitar erros na
prescrição, como parte importante da equipe médica,
assim como a urgência de implementar os cuidados far-
macêuticos em todos os estabelecimentos dos Centros de
Saúde no México.
UNITERMOS: Medicamentos/estudo de utilização. Medi-
camentos/uso racional. Medicamentos/erros de prescri-
ção. Atenção farmacêutica.
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